Literature DB >> 3018622

Baclofen activates two distinct receptors in the rat spinal cord and guinea pig ileum.

J Sawynok.   

Abstract

Following intrathecal injection, pretreatment with both D-baclofen and 5-aminovaleric acid (5-AV) inhibited the antinociceptive effect of L-baclofen, but homotaurine (3-aminopropane sulphonic acid, APS) was inactive as an antagonist (rank order D-baclofen greater than 5-AV greater than APS = 0). In an established GABAB system, the electrically stimulated guinea pig longitudinal muscle myenteric plexus preparation, APS and 5-AV but not D-baclofen reduced the inhibitory effect of L-baclofen (APS = 5-AV greater than D-baclofen = 0). Receptors with which baclofen interacts in the spinal cord to produce antinociception differ from GABAB receptors with respect to the rank order of potency of antagonists as well as close structural analogs, and these criteria could be used for characterization of such receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018622     DOI: 10.1016/0028-3908(86)90098-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

1.  5-aminovaleric acid suppresses the development of severe seizures in the methionine sulfoximine model of mesial temporal lobe epilepsy.

Authors:  Roni Dhaher; Eyiyemisi C Damisah; Helen Wang; Shaun E Gruenbaum; Caroline Ong; Hitten P Zaveri; Benjamin F Gruenbaum; Tore Eid
Journal:  Neurobiol Dis       Date:  2014-03-14       Impact factor: 5.996

Review 2.  Spasticity and drug therapy.

Authors:  E W Wuis
Journal:  Pharm Weekbl Sci       Date:  1987-10-16

3.  Effects of the putative antagonists phaclofen and delta-aminovaleric acid on GABAB receptor biochemistry.

Authors:  T N Robinson; A J Cross; A R Green; J M Toczek; B R Boar
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

4.  CGP 35348, a new GABAB antagonist, prevents antinociception and muscle-relaxant effect induced by baclofen.

Authors:  M Malcangio; C Ghelardini; A Giotti; P Malmberg-Aiello; A Bartolini
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.